GS
BRNS

GTS Securities’s Barinthus Biotherapeutics BRNS Stock Holding History

GTS Securities’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.9K Buy
+73,210
New +$48.2K ﹤0.01% 1441

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

GTS Securities's BRNS Position: Q1 2026 in Review

GTS Securities opened a new position in Barinthus Biotherapeutics (BRNS) in Q1 2026: 73,210 shares worth $41.9K. The stake represents ﹤0.01% of the portfolio and ranks #1441 among its holdings.

14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • GTS Securities held 73,210 shares of Barinthus Biotherapeutics worth $41.9K as of Q1 2026.
  • Barinthus Biotherapeutics was a new GTS Securities position in Q1 2026.
  • Barinthus Biotherapeutics made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1441 holding.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.